Source link : https://www.newshealth.biz/health-news/biohaven-anxiety-treatment-fails-in-late-stage-study/

(Reuters) – Biohaven Pharmaceutical Holding Company Ltd on Monday said its treatment for anxiety disorder failed to meet the main goal in a late-stage study, sending its shares down 25%.
In the study, patients receiving the experimental drug, troriluzole, twice everyday did not show improvement in anxiety symptoms, compared to a placebo.

Reporting By Mrinalika Roy in Bengaluru; Editing by Saumyadeb Chakrabarty

Our Standards:The Thomson Reuters Trust Principles.

Source link : http://feeds.reuters.com/~r/reuters/healthNews/~3/lFS8XLipL5c/biohaven-anxiety-treatment-fails-in-late-stage-study-idUSKBN2041GB

Author :

Publish date : 2020-02-10 12:42:42

Copyright for syndicated content belongs to the linked Source.

Author : News Health

Publish date : 2020-02-10 12:42:42

Copyright for syndicated content belongs to the linked Source.